http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
백병준,유명상,신재민,김효진,박훈,김장묵,오천환 순천향의학연구소 2003 Journal of Soonchunhyang Medical Science Vol.9 No.2
Background and Objectives : Paranasal sinus cancer is rare when compared with cancers of other sites. Because paranasal sinus is anatomically located adjacent to the orbit and skull base, it is difficult to remove the tumor completely with tumor free margin in advanced paranasal sinus cancer. This report was conducted to investigate clinical characteristics, histologic type and treatment outcome of paranasal sinus cancer. Material and Methods : Twenty-six cases with paranasal sinus cancer diagnosed at the Department of otolaryngology-Head and Neck Surgery, Soonchunhyang Cheonan Hospital from January 1991 to September 2000 were studied by chart review, telephone interview and letters retrospectively. Results : The male to female ratio was 4.2 : 1. Most patients were 6th and 7th decade. The maxillary sinus was the most commonly affected site(61.5%), followed by the ethmoid sinus(34.6%). The most common histologic type of malignancy was squamous cell carcinoma(57.6%), followed by adenocarcinoma(19.2%). Most patients presented with T_(3)/T_(4) or locally advanced disease, N_(0)(91.3%), and M_(0)(100%) Sixtynine pertcent of this study group underwent sugery as part of a mutimodality curative treatment plan or alone as curative treatment. Eighteen patients(69.2%) developed recurrent disease at a median time of 278 days after initial treatment. Kaplan-Meier analysis revealed the 5-year disease specific survival was 34.6%. Conclusion : Most patients with paranasal sinus cancer presented with locally advanced disease. Adanced T stage was highly predictive of poor prognosis. Recurrence rate was high and mostly occured within the second year after treatment.
Small Cell Lung Cancer Cell Line을 이용한 Xenoplanted nude mice에서 방서선 치료후 종양의 변화 관찰에 관한 연구
김동욱,유명상,김재욱,이병돈,장혁순 순천향의학연구소 2002 Journal of Soonchunhyang Medical Science Vol.8 No.1
Recently, combination of ionizing radiation with inhibitors of angiogenesis has been reported to improve tumor eradication compared to treatment with irradiation alone. However, the mechanism of this effect have not been defined. For this pupose we established a non-small cell lung cancer model in nude mice. Tumor vascularization was visualized in vivo by MRI using gadolinium-DTPA as contrast agent. Further, cryosections were produced exactly in the MRI slice positions. Since we were interested to examine formation of recurrent tumor irradiation was performed with a single fraction of 6 Gy. This dose caused a partial remission followed by recurrent tumor growth 25 to 35 days after therapy. The process of partial remission as well as formation of the recurrent tumor was examined in 35 nude mice analysing the following parameters: (1) contrast agent enhancement using high-resolution MRI, (2) proliferation of tumor cells and fibroblast using Ki-67 immunohistochemistry, (3) formation of microvessels using CD31 immunohistochemistry. The latter analyses lead to differentiation of three stages. Stage 1(day 1 to 15 after irradiation) was characterized by increasing area of dead cell mass in hematoxylin-eosin stained slides that corresponded to a decrease in tumor cellproliferation as well as contrast agent enhancement. The percentage of Ki-67 positive tumor cells decreased from initially 45.1 ±6.0 to 1.4 %±1.2 % on day 15. Stage 2(days 6 to 20 after irradiation; overlapping with stage 1) was characterized by proliferation of fibroblast leading to formation of fibrotic septae with abundant microvessels. Already during late stage 2 MRI identified new contrast agent enhancing areas. Stage 3(day 20 to 40 after irradiation) was characterized by new tumor cell proliferation. Interestingly, tumor cells almost exclusively proliferated in the direct neighbourhood of the fibroblasts and blood vessels was a condition prior to foramtion of recurrent tumor tissue. Thus our results are in contrast with the view that tumors or recurrent tumors begin as avascular masses that later induce neovascularization. With respect to clinical practice our results suggest that (1) adjuvant anti-angiogenic therapy should not be limited to the day of irradiation but should cover a critical period until day 5 to day 20 after radiotherapy, (2) adjuvant therapy should also include inhibition of fibroblast proliferation, (3) MRI can identify a recurrent tumor 10 to 15 days before occurrence of new tumor growth.